Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series.
The cause of the selective melanocyte destruction in vitiligo may be due to an autoimmune disorder. A series of 15 patients with vitiligo were treated with a topical immunomodulator, tacrolimus ointment 0.1%, twice daily for a minimum of 45 days. Thirteen patients (87%) experienced at least partial repigmentation, and 3 of those patients had greater than 75% repigmentation. Patients with the greatest treatment response likely benefited from concomitant natural sunlight exposure. Further studies investigating the safety and efficacy of tacrolimus ointment either as monotherapy or in combination with other therapeutic measures are warranted.
Tanghetti
Emil A
EA
Center for Dermatology and Laser Surgery, Sacramento, California, USA. et@mgci.com
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009824:Ointments; D011446:Prospective Studies; D012880:Skin Pigmentation / Q000187:drug effects*; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014820:Vitiligo / Q000188:drug therapy*
D007166:Immunosuppressive Agents; D009824:Ointments; D016559:Tacrolimus